Literature DB >> 12187194

When is medical prophylaxis cost-effective for recurrent calcium stones?

Paramjit S Chandhoke1.   

Abstract

PURPOSE: Medical management is generally recommended for recurrent calcium stones to prevent future episodes. However, in this era of extracorporeal shock wave lithotripsy and outpatient ureteroscopy it is not known whether medical prophylaxis is more cost-effective than treatment of recurrent stone episodes. The cost of medical prophylaxis was compared with the cost of clinically managing recurrent stone episodes, and the stone recurrence rate without prophylaxis (stone frequency) at which these 2 treatment approaches became cost equivalent was determined.
MATERIALS AND METHODS: An international cost survey was conducted in 10 countries to compare costs of medical prophylaxis and managing recurrent acute stone episodes. Costs of an acute stone episode included an emergency room visit, associated radiographic imaging to confirm diagnosis of a symptomatic stone and outpatient treatment of upper urinary tract stones that did not pass spontaneously. Costs of medical management included an initial limited metabolic evaluation, drug therapy, a followup office visit every 6 months that included a 24-hour urinalysis and radiographic imaging of the kidneys, ureters and bladder once a year.
RESULTS: Costs of medical prophylaxis and managing an acute stone episode varied significantly from country to country. The stone frequency at which costs of these management options became equivalent ranged from 0.3 to 4 stone episodes a year.
CONCLUSIONS: Medical management of a first stone episode is not cost-effective. Cost analysis should be individualized for specific health care plans to determine which practice patterns are most cost-effective for a particular patient with recurrent calcium stone formation.

Entities:  

Mesh:

Year:  2002        PMID: 12187194     DOI: 10.1097/01.ju.0000024921.93877.f1

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  19 in total

Review 1.  Kidney stones.

Authors:  Malvinder S Parmar
Journal:  BMJ       Date:  2004-06-12

2.  Metabolic testing of the first-time calcium oxalate stone former: Is it indicated? No.

Authors:  Hassan Razvi
Journal:  Can Urol Assoc J       Date:  2010-06       Impact factor: 1.862

3.  [Economic aspects of evidence-based metaphylaxis].

Authors:  W L Strohmaier
Journal:  Urologe A       Date:  2006-11       Impact factor: 0.639

Review 4.  Management of kidney stones.

Authors:  Nicole L Miller; James E Lingeman
Journal:  BMJ       Date:  2007-03-03

Review 5.  [The future of ESWL].

Authors:  K U Köhrmann; D Neisius; J Rassweiler
Journal:  Urologe A       Date:  2008-05       Impact factor: 0.639

6.  Feasibility of a Telemedicine-Administered, Pharmacist-Staffed, Protocol-Driven, Multicenter Program for Kidney Stone Prevention in a Large Integrated Health Care System: Results of a Pilot Program.

Authors:  Mark E Gasparini; Toby W Chang; Mark St Lezin; John E Skerry; Andy Chan; Krishna A Ramaswamy
Journal:  Perm J       Date:  2019-11-01

7.  Effect of blind treatment on stone disease.

Authors:  Y M Fazil Marickar; Abiya Salim; Adarsh Vijay
Journal:  Urol Res       Date:  2009-12-08

8.  International comparison of cost effectiveness of medical management strategies for nephrolithiasis.

Authors:  Yair Lotan; Jeffrey A Cadeddu; Margaret S Pearle
Journal:  Urol Res       Date:  2005-05-28

9.  The economics of stone disease.

Authors:  Noah E Canvasser; Peter Alken; Michael Lipkin; Stephen Y Nakada; Hiren S Sodha; Abdulkadir Tepeler; Yair Lotan
Journal:  World J Urol       Date:  2017-01-20       Impact factor: 4.226

10.  Family history in stone disease: how important is it for the onset of the disease and the incidence of recurrence?

Authors:  Hakan Hasbey Koyuncu; Faruk Yencilek; Bilal Eryildirim; Kemal Sarica
Journal:  Urol Res       Date:  2010-01-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.